CALL - SPRINTER OPEN END - NOVO-NORDISK B | Market Closed - Börse Stuttgart 11:49:18 20/06/2024 am IST | ||
| 23.29 EUR | +0.22% |
|
| Current month | +8.38% | ||
| 1 month | +8.78% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 20/24/20 | 23.29 | +0.22% |
| 19/24/19 | 23.24 | -0.13% |
| 18/24/18 | 23.27 | -1.73% |
| 17/24/17 | 23.68 | +0.85% |
| 14/24/14 | 23.48 | +0.21% |
Delayed Quote Börse Stuttgart
Last update June 20, 2024 at 11:49 am IST
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VN7F73 |
| ISIN | DE000VN7F730 |
| Date issued | 06/02/2017 |
| Strike | 111.5 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.11 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 23.68 € |
|---|---|
| Lowest since issue | 0.045 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.8
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.99%
- Stock Market
- Certificates
- Certificat
